Subtype
Malignant Neoplasm of Unknown Primary
CI-CAN-00001150CUPExplore in graph →
4,158 active trials54 approved drugs532 evidence items
- NCIt
- C8566
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001150CUPExplore in graph →
Clinical trials
14,253 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,895)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02425072 | NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | John VillanoOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT02108782 | Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 0 | Jul 19, 2017 | clinicaltrials |
| NCT01176500 |
| A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 2, 2017 |
| clinicaltrials |
| NCT02856867 | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)(MEGAN) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 9, 2017 | clinicaltrials |
| NCT02227914 | Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | AmgenINDUSTRY | 1 | May 2, 2017 | clinicaltrials |
| NCT02997956 | Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) | withdrawn | Phase 1 / Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer(PRIMIER) | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Apr 4, 2017 | clinicaltrials |
| NCT02685306 | A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer | withdrawn | Phase 2 | 0 | Peregrine PharmaceuticalsINDUSTRY | 0 | Mar 9, 2017 | clinicaltrials |
| NCT01640847 | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases | withdrawn | Phase 2 | 0 | ImunonINDUSTRY | 0 | Feb 7, 2017 | clinicaltrials |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 25, 2017 | clinicaltrials |
| NCT00598858 | Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate(2007-5904) | withdrawn | Phase 2 | 0 | John P. FruehaufOTHER | 0 | Dec 8, 2016 | clinicaltrials |
| NCT02661100 | A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | withdrawn | Phase 1 / Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 7, 2016 | clinicaltrials |
| NCT01335074 | Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 1 / Phase 2 | 0 | Philipps University MarburgOTHER | 1 | Nov 15, 2016 | clinicaltrials |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 12, 2016 | clinicaltrials |
| NCT02649530 | A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of Michigan Rogel Cancer CenterOTHER | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01964235 | Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 7 | Sep 1, 2016 | clinicaltrials |
| NCT02539017 | The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer | withdrawn | Phase 2 | 0 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Aug 10, 2016 | clinicaltrials |
| NCT01820312 | A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | Aug 8, 2016 | clinicaltrials |
| NCT02152059 | A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy | withdrawn | Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00800969 | Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT01048086 | 90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET) | withdrawn | Phase 2 | 0 | University of IowaOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT01953406 | The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Seoul National University HospitalOTHER | 1 | Apr 27, 2016 | clinicaltrials |
| NCT02119728 | Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 21, 2016 | clinicaltrials |
| NCT02143622 | Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 21, 2016 | clinicaltrials |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 0 | Mar 24, 2016 | clinicaltrials |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | withdrawn | Phase 2 | 0 | Centre Leon BerardOTHER | 1 | Feb 25, 2016 | clinicaltrials |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Erin BertinoOTHER | 0 | Oct 30, 2015 | clinicaltrials |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | Oct 8, 2015 | clinicaltrials |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University Hospital of CreteOTHER | 1 | Oct 7, 2015 | clinicaltrials |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2015 | clinicaltrials |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling | withdrawn | Phase 2 | 0 | Toni Choueiri, MDOTHER | 1 | Sep 1, 2015 | clinicaltrials |
| NCT00574483 | Treatment of Advanced Renal Cell Carcinoma With Quinacrine | withdrawn | Phase 2 | 0 | Cleveland BioLabsINDUSTRY | 1 | Aug 3, 2015 | clinicaltrials |
| NCT00176280 | Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | University of KentuckyOTHER | 0 | Jun 18, 2015 | clinicaltrials |
| NCT01775280 | Response of Hepatic Tumors to Radioembolization(RESRAD) | withdrawn | Phase 2 | 0 | University of ZurichOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT00119314 | Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | May 27, 2015 | clinicaltrials |
| NCT02235324 | Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00253526 | Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Apr 28, 2015 | clinicaltrials |
| NCT00469469 | Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma | withdrawn | Phase 2 | 0 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Apr 22, 2015 | clinicaltrials |
| NCT01953952 | Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer | withdrawn | Phase 2 | 0 | Radiation Therapy Oncology GroupNETWORK | 1 | Mar 20, 2015 | clinicaltrials |
| NCT02033538 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02034968 | Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02041819 | Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02011594 | Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT02070419 | TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Dec 2, 2014 | clinicaltrials |
| NCT01465815 | Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) | withdrawn | Phase 1 / Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Nov 19, 2014 | clinicaltrials |
| NCT00808145 | Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) | withdrawn | Phase 2 | 0 | Lahey ClinicOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer | withdrawn | Phase 2 | 0 | University of Southern CaliforniaOTHER | 0 | Sep 10, 2014 | clinicaltrials |
| NCT01859182 | Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 9, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Aug 10, 2017source: clinicaltrials